AbCellera Biologics (NASDAQ:ABCL - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.04, Zacks reports. AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. The firm had revenue of $5.10 million during the quarter, compared to the consensus estimate of $7.58 million.
AbCellera Biologics Stock Down 8.9 %
Shares of ABCL traded down $0.23 on Monday, reaching $2.36. The stock had a trading volume of 3,727,039 shares, compared to its average volume of 2,215,934. The firm has a market capitalization of $697.06 million, a PE ratio of -3.87 and a beta of 0.42. AbCellera Biologics has a twelve month low of $2.31 and a twelve month high of $5.13. The firm has a 50-day moving average of $3.10 and a 200 day moving average of $2.84.
Wall Street Analyst Weigh In
Several research firms have recently commented on ABCL. Stifel Nicolaus reduced their price target on AbCellera Biologics from $12.00 to $10.00 and set a "buy" rating for the company in a report on Friday. KeyCorp decreased their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Finally, Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a report on Monday.
View Our Latest Research Report on ABCL
AbCellera Biologics Company Profile
(
Get Free Report)
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
Read More
Before you consider AbCellera Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.
While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
